7-Amino-1,3-dimethyl-alloxazin | 21620-13-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 7-Amino-1,3-dimethyl-alloxazin
• 英文别名: 8-amino-1,3-dimethylbenzo[g]pteridine-2,4(1H,3H)-dione；8-amino-1,3-dimethylbenzo[g]pteridine-2,4-dione
• CAS: 21620-13-3
• 化学式: C₁₂H₁₁N₅O₂
• mdl: MFCD00575944
• 分子量: 257.252
• InChiKey: QBLHBGSNDGMZKF-UHFFFAOYSA-N

物化性质

• 沸点：
  510.5±60.0 °C(Predicted)
• 密度：
  1.476±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1,3-dimethylvioluric acid 生成 7-Amino-1,3-dimethyl-alloxazin
  参考文献：
  名称：

  Piloty; Finckh, Justus Liebigs Annalen der Chemie, 1904, vol. 333, p. 44

  摘要：

  DOI：

文献信息

• PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT
  申请人：NATIONAL CANCER CENTER

  公开号：US20220033405A1

  公开（公告）日：2022-02-03

  The present invention relates to a pharmaceutical composition for preventing, treating or alleviating cancer, containing a PLK1 inhibitor as an active ingredient, and a compound according to the present invention selectively binds to PBD of PLK1, thereby having advantages of high selectivity and binding affinity for PLK1 and low toxicity. Therefore, a PLK inhibitor compound according to the present invention can be effectively used as an anticancer agent by inhibiting the growth of various cancer cells, and can be expected to exhibit synergistic effects with existing developed anticancer agents through co-administration, in addition to individual administration thereof.

  本发明涉及一种用于预防、治疗或缓解癌症的药物组合物，包含PLK1抑制剂作为活性成分。本发明的化合物选择性地结合到PLK1的PBD上，因此具有高选择性和结合亲和力，且毒性较低的优点。因此，根据本发明的PLK抑制剂化合物可以通过抑制各种癌细胞的生长有效地用作抗癌剂，并且可以通过联合使用与现有开发的抗癌剂表现出协同效应，除了单独使用之外。
• Screening methods for identifying specific Staphylococcus aureus inhibitors
  申请人：Guenther Richard H.

  公开号：US10316371B2

  公开（公告）日：2019-06-11

  Methods of inhibiting S. aureus propagation, and screening for compounds that inhibit S. aureus propagation, are described. A method of inhibiting S. aureus propagation comprises either inhibiting or stabilizing ribosomal binding of a specific S. aureus tRNA in the S. aureus by an amount sufficient to inhibit S. aureus protein expression. A method of screening for compounds useful for inhibiting S. aureus propagation comprises contacting a specific S. aureus tRNA to a ribosome that binds that tRNA in the presence of the test compound and an mRNA that codes for methionine and arginine (i.e., includes the sequence AUGAGA), and then determining whether the compound inhibits the binding of that tRNA.

  本文描述了抑制金黄色葡萄球菌繁殖的方法和筛选抑制金黄色葡萄球菌繁殖的化合物的方法。一种抑制金黄色葡萄球菌繁殖的方法包括抑制或稳定金黄色葡萄球菌中特定金黄色葡萄球菌 tRNA 的核糖体结合，其抑制量足以抑制金黄色葡萄球菌蛋白质的表达。筛选可抑制金黄色葡萄球菌繁殖的化合物的方法包括将特异的金黄色葡萄球菌tRNA与核糖体接触，该核糖体在试验化合物和编码蛋氨酸和精氨酸（即包括序列AUGAGA）的mRNA存在的情况下结合该tRNA，然后确定该化合物是否抑制该tRNA的结合。
• SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS
  申请人：Trana Discovery, Inc.

  公开号：EP2691542A1

  公开（公告）日：2014-02-05
• [EN] SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS<br/>[FR] PROCÉDÉS DE CRIBLAGE POUR L'IDENTIFICATION D'INHIBITEURS SPÉCIFIQUES DE STAPHYLOCCOCUS AUREUS
  申请人：TRANA DISCOVERY INC

  公开号：WO2012135416A1

  公开（公告）日：2012-10-04

  Methods of inhibiting S. aureus propagation, and screening for compounds that inhibit S. aureus propagation, are described. A method of inhibiting S. aureus propagation comprises either inhibiting or stabilizing ribosomal binding of a specific S. aureus tRNA in the S. aureus by an amount sufficient to inhibit S. aureus protein expression. A method of screening for compounds useful for inhibiting S. aureus propagation comprises contacting a specific S. aureus tRNA to a ribosome that binds that tRNA in the presence of the test compound and an mRNA that codes for methionine and arginine (i.e., includes the sequence AUGAGA), and then determining whether the compound inhibits the binding of that tRNA.
• [EN] PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING ACTIVATION INHIBITOR OF PLK1 AS ACTIVE INGREDIENT<br/>[FR] COMPOSITION PHARMACEUTIQUE PERMETTANT DE PRÉVENIR OU DE TRAITER LE CANCER CONTENANT UN INHIBITEUR DE L'ACTIVATION DE PLK1 EN TANT QUE PRINCIPE ACTIF<br/>[KO] PLK1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
  申请人：NAT CANCER CT

  公开号：WO2020111325A1

  公开（公告）日：2020-06-04

  본 발명은 PLK1의 활성 억제제를 유효성분으로 포함하는 암 예방, 치료 또는 개선용 약학적 조성물에 관한 것으로 본 발명에 따른 상기 화합물은 PLK1의 PBD에 선택적으로 결합함으로써, PLK1에 대한 높은 선택성과 결합친화성, 및 저독성의 이점을 갖는다. 따라서, 본 발명에 따른 PLK1 활성 억제제 화합물은 다양한 암세포의 성장을 저해함으로써 항암제로 유용하게 이용될 수 있을 것이며, 단독투여 이외에도 기존에 개발된 항암제와의 병용투여를 통한 시너지효과를 기대할 수 있다.